Kim Kardashian Instagram post draws FDA warning

The FDA calls foul on Kardashian
The FDA calls foul on Kardashian

Kim Kardashian may be famous for her selfies, but the Food and Drug Administration wasn't a fan of her latest one.

An Instagram picture featuring Kardashian, morning sickness drug Diclegis and accompanying text promoting the drug's benefits garnered more than 450,000 "likes" but brought about a formal FDA warning letter for the drug's manufacturer. (Tweet This)

Part of the letter says, "The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information."

The posts promoting the drug have since been taken down, but Kardashian, who was paid to promote the drug, originally claimed it made her feel "a lot better and most importantly, it's been studied and there was no increased risk to the baby."

Read More Kermit and Miss Piggy are the latest power couple to split

Duchesnay, the pharmaceutical company behind the drug, told CNBC that while Kim was paid to promote her experience with the drug she had found it on her own accord through her family OB-GYN. The company said it would take quick action in responding to the FDA's letter.

"Duchesnay USA takes its regulatory responsibilities very seriously, and acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations," the company said.

Read More What's it like being a Victoria's Secret model?

The FDA said seeing misleading promotional materials from Duchesnay was particularly troubling since the company had already been cautioned in 2013 for misleading promotional activities.

The FDA warning letter requests Duchesnay offer corrections to the claims "using the same media" for the same audience. That could mean a revised selfie for Kim's 42.4 million followers.

Kardashian did not immediately respond to a request for comment from CNBC.

—CNBC's Steve Kopack and Jim Forkin contributed to this report.